Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Japan to Receive 1.6 Million Courses of MSD’s COVID-19 Drug
November 11, 2021
- Pfizer’s COVID-19 Booster Now in Line for Approval for Age 18-Plus
November 11, 2021
- Japan’s Healthcare Spend Grows to 44.4 Trillion Yen in FY2019
November 10, 2021
- Govt Panel Urges Support for Domestic Development and Production of COVID-19 Vaccines, Drugs to Ensure Supply
November 10, 2021
- MOF Calls for Stepwise Cuts in 2% Adjustment Rate, Timeline towards Abolishment
November 9, 2021
- Japan Drug Spending Up 2.3% Annually Since 2000, Outstripping GDP Growth: MOF
November 9, 2021
- MHLW to Conduct Follow-Up Health Survey on COVID-19 Vaccinations
November 9, 2021
- MHLW Panel Tables Decision on Efient’s Preventive Use for ICD Recurrences; Lilly's Migraine Med, Jardiance's Heart Failure Indication OK'ed
November 9, 2021
- Chuikyo Split over 2% Adjustment Rate, Off-Year Re-Pricing; JPWA Says Wholesalers Are in Dire Straits
November 8, 2021
- Industry Pushes PMP Coverage for Additional Indications, Payers See This Need Too but Only for Certain Products: Chuikyo
November 8, 2021
- Chuikyo Calls for Combining Multiple Steps to Curb Spend for Potential Super Big Sellers Like Aducanumab, No Objection to Listing
November 8, 2021
- JGA Sees New Generics as Financial Resources Necessary to Increase Production Capacity: Chuikyo Hearing
November 8, 2021
- Japan Approves Ronapreve to Prevent Symptomatic COVID-19
November 5, 2021
- Herceptin’s Salivary Cancer Use Sails through PAFSC; Label Expansions for I/O Drugs, Lorbrena in Line for Approval
November 5, 2021
- Ronapreve Clears Key Panel for COVID-19 Prevention, SC Use
November 5, 2021
- Pfizer’s COVID-19 Booster Up for PAFSC Review on Nov. 10
November 5, 2021
- Booster Shots to Start with Pfizer Vaccine: MHLW
November 2, 2021
- G20 Ministers Vow to Boost Vaccine Supply to Developing Countries
November 2, 2021
- Noda, Tokashiki, More in LDP Healthcare Clique Lose Seats in Lower House Poll
November 1, 2021
- Japan Panel OKs Booster Shots for All People Who Took 2 Doses
October 29, 2021
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…